Find clinical trials for COVID-19 in Hanyang, Seoul
CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
Related conditions:
COVID-19 trials near Hanyang, Seoul, KOR:
IV compared to remdesivir IV alone for the treatment of symptomatic COVID-19 in severely immunocompromised adult participants who a...
Phase 3
Seoul, Seoul-teukbyeolsi [seoul], South Korea and 157 other locations
The immunogenicity and safety of AdCLD-CoV19-1 OMI (5.0x10\^10 VP (0.5 mL)/dose/Vial) administered as a booster in healthy adults aged 19 years old a...
Phase 3
Seoul, Korea, Republic of and 16 other locations
This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Ratutrelvir in Patients With Mild to Moderate COVID-19...
Phase 2
Seoul, Eunpyeong-gu, South Korea and 14 other locations
This Phase 1, multi-center, randomized, double-blind, placebo-controlled, dose-escalation study evaluates the safety, tolerability, and immunogenicit...
Phase 1
Seoul, South Korea and 2 other locations
legal age for adult in each country) with confirmed mild or moderate COVID-19 tested positive with a real time reverse transcriptio...
Phase 2, Phase 3
Seoul, Korea, Republic of and 2 other locations
Parallel-treatment Group, Adaptive Design, Multi-center, Phase 2b/3 Trial to Evaluate Efficacy and Safety of NuSepin® Intravenous Infusion in COVID...
Phase 2, Phase 3
Incheon, Namdong-gu, Korea, Republic of
Researchers are looking for other ways to prevent severe illness from COVID-19. COVID-19 is a virus that most oft-...
Phase 3
Seoul, South Korea and 224 other locations
The purpose of the study is to evaluate whether ibuzatrelvir is effective and safe in adults and adolescents with COVID-19 who do n...
Phase 3
Seoul, Seoul-teukbyeolsi [seoul], South Korea and 259 other locations
Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Preventive Vaccine 'GC4006A' in Healthy Adults Aged 19 to ...
Phase 1
Seoul, South Korea
This study is to evaluate the safety, reactogenicity, and immunogenicity of the QTP104 vaccine against SARS-CoV-2 infection in healthy adults.
Phase 1
Seoul, Korea, Republic of and 1 other location
Clinical trials
Research sites
Resources
Legal